| Literature DB >> 23083433 |
Håvard Dale1, Anne M Fenstad, Geir Hallan, Leif I Havelin, Ove Furnes, Søren Overgaard, Alma B Pedersen, Johan Kärrholm, Göran Garellick, Pekka Pulkkinen, Antti Eskelinen, Keijo Mäkelä, Lars B Engesæter.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2012 PMID: 23083433 PMCID: PMC3488170 DOI: 10.3109/17453674.2012.733918
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Patient and procedure characteristics for the primary THAs included, and number of primary THAs excluded over the 3 time periods
| 1995-1999 | 2000-2004 | 2005-2009 | 1995-2009 | |
|---|---|---|---|---|
| Number of THAs included | 113,280 | 147,823 | 171,065 | 432,168 |
| Age (%) | ||||
| <40 years | 2 | 1 | 1 | 1 |
| 40–59 years | 17 | 18 | 17 | 17 |
| 60–69 years | 29 | 29 | 32 | 30 |
| 70–79 years | 38 | 37 | 35 | 36 |
| 80–89 years | 14 | 15 | 15 | 15 |
| ≥90 years | 1 | 1 | 1 | 1 |
| Sex (%) Female | 63 | 62 | 61 | 61 |
| Diagnosis (%) | ||||
| Osteoarthritis | 76 | 80 | 83 | 80 |
| Hip fracture | 10 | 7 | 6 | 8 |
| Inflammatory disease | 5 | 4 | 2 | 4 |
| Childhood hip disease | 4 | 4 | 3 | 3 |
| Femoral head necrosis | 2 | 2 | 2 | 2 |
| Other diagnoses | 2 | 3 | 3 | 3 |
| Prosthesis (%) | ||||
| Monoblock | 22 | 10 | 2 | 10 |
| Modular | 78 | 90 | 98 | 90 |
| Fixation (%) | ||||
| Uncemented | 13 | 16 | 30 | 21 |
| Cemented | 76 | 71 | 56 | 67 |
| Hybrid | 10 | 10 | 6 | 9 |
| Inverse hybrid | 1 | 3 | 8 | 4 |
| Cement (%) | ||||
| No???? | 13 | 16 | 30 | 21 |
| With antibiotics | 71 | 79 | 69 | 73 |
| Without antibiotics | 15 | 5 | 1 | 6 |
| Country (%) | ||||
| Denmark | 14 | 20 | 22 | 21 |
| Norway | 23 | 21 | 19 | 20 |
| Sweden | 45 | 42 | 41 | 42 |
| Finland | 19 | 17 | 18 | 18 |
| Number of THAs excluded | 10,540 | 3,303 | 6,169 | 9,922 (4.4%) |
Figure 3.A graphical display of the relationship between relative risk of revision due to infection and time after primary THAs for the period 2000–2004 (left panel) and 2005–2009 (right panel) compared to 1995–1999 (blue lines). Smoothed Schoenfeld residuals adjusted for age, sex, diagnosis, prosthesis and cement (solid lines) with 95% confidence intervals (broken lines).
Relative risk of revision due to infection of primary THAs in the NARA with 1-16 years of follow-up. Adjusted for age, sex, diagnosis, prosthesis, and cement
| Period | Number | Number of | Adjusted risk ratio | 95% | p-value | |
|---|---|---|---|---|---|---|
| All THAs | 1995–1999 | 113,280 | 778 | 1 | ||
| 2000–2004 | 147,823 | 937 | 1.1 | 1.0–1.2 | 0.03 | |
| 2005–2009 | 171,065 | 1,063 | 1.6 | 1.4–1.7 | <0.001 | |
| Uncemenxted THAs | 1995–1999 | 15,177 | 87 | 1 | ||
| 2000–2004 | 23,553 | 147 | 1.4 | 1.0–1.8 | 0.03 | |
| 2005–2009 | 51,445 | 308 | 1.9 | 1.5–2.5 | <0.001 | |
| Cemented THAs | 1995–1999 | 86,177 | 538 | 1 | ||
| 2000–2004 | 105,421 | 641 | 1.2 | 1.1–1.3 | 0.006 | |
| 2005–2009 | 96,455 | 619 | 1.7 | 1.5–2.0 | <0.001 | |
| Hybrid THAs | 1995–1999 | 11,369 | 149 | 1 | ||
| 2000–2004 | 15,163 | 125 | 0.8 | 0.6–1.0 | 0.02 | |
| 2005–2009 | 10,390 | 63 | 0.8 | 0.6–1.1 | 0.2 | |
| Inverse hybrid THAs | 1995–1999 | 556 | 4 | 1 | ||
| 2000–2004 | 3,685 | 24 | 1.3 | 0.4–4.0 | 0.6 | |
| 2005–2009 | 12,775 | 73 | 1.6 | 0.5–4.6 | 0.4 | |
| Cemented modular | 1995–1999 | 37,848 | 208 | 1 | ||
| 2000–2004 | 69,052 | 374 | 1.1 | 0.9–1.3 | 0.2 | |
| 2005–2009 | 75,929 | 467 | 1.7 | 1.4–2.0 | <0.001 |
a Adjusted for age and sex.
Figure 1.Adjusted cumulative revision rates for THAs revised due to infection in 3 time periods of primary surgery, for all THAs (upper left panel) and 5 subgroups of THAs. Adjusted for age, sex, diagnosis, prosthesis, and cement. *Adjusted for age and sex only.
Figure 2.Graphical display of the relationship between year of primary surgery and relative risk of revision due to infection (with 95% CI), for all THAs (upper left panel) and 5 subgroups of THAs. The broken lines represent no difference in relative risk from the beginning of the period (RR = 1). Adjusted for age, sex, diagnosis, prosthesis, and cement. *Adjusted for age and sex.
Adjusted cumulative 5-year revision rates of primary THAs in the NARA. Adjusted for age, sex, diagnosis, prosthesis, and cement
| Period | Number | Cumulative 5-years revision rate | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kaplan-Meier | Adjusted | Adjusted | Adjusted | |||||||
| All THAs | 1995–1999 | 113,280 | 0.54 | (0.49–0.58) | 0.46 | (0.42–0.50) | 1.41 | (1.34–1.49) | 3,34 | (3.22–3.45) |
| 2000–2004 | 147,823 | 0.57 | (0.53–0.61) | 0.54 | (0.50–0.58) | 0.81 | (0.77–0.86) | 3.01 | (2.92–3.10) | |
| 2005–2009 | 171,065 | 0.73 | (0.68–0.77) | 0.71 | (0.66–0.76) | 1.00 | (0.93–1.07) | 3.30 | (3.19–3.41) | |
| Uncemented THAs | 1995–1999 | 15,177 | 0.36 | (0.26–0.45) | 0.34 | (0.25–0.44) | 1.32 | (1.13–1.50) | 4.39 | (4.05–4.72) |
| 2000–2004 | 23,553 | 0.55 | (0.45–0.65) | 0.52 | (0.43–0.61) | 0.85 | (0.73–0.97) | 4.28 | (4.02–4.54) | |
| 2005–2009 | 51,445 | 0.70 | (0.61–0.78) | 0.65 | (0.57–0.74) | 1.21 | (1.08–1.34) | 4.24 | (4.02–4.45) | |
| Cemented THAs | 1995–1999 | 86,177 | 0.51 | (0.47–0.56) | 0.43 | (0.38–0.48) | 1.34 | (1.25–1.43) | 2.82 | (2.70–2.94) |
| 2000–2004 | 105,421 | 0.56 | (0.51–0.60) | 0.52 | (0.48–0.57) | 0.74 | (0.68–0.79) | 2.53 | (2.43–2.63) | |
| 2005–2009 | 96,455 | 0.74 | (0.68–0.81) | 0.74 | (0.67–0.80) | 0.85 | (0.77–0.94) | 2.93 | (2.80–3.07) | |
| Hybrid THAs | 1995–1999 | 11,369 | 0.94 | (0.76–1.12) | 0.88 | (0.70–1.06) | 1.82 | (1.55–2.09) | 4.92 | (4.50–5.34) |
| 2000–2004 | 15,163 | 0.72 | (0.58–0.85) | 0.67 | (0.53–0.80 | 0.98 | (0.81–1.14) | 3.79 | (3.48–4.10) | |
| 2005–2009 | 10,390 | 0.72 | (0.54–0.90) | 0.67 | (0.50–0.85) | 1.00 | (0.75–1.25) | 3.86 | (3.41–4.31) | |
| Inverse hybrid THAs | 1995–1999 | 556 | 0.77 | (0.02–1.51) | 0.36 | (0–1.38) | 2.36 | (0.97–3.75 | 5.59 | (3.65–7.54) |
| 2000–2004 | 3,685 | 0.53 | (0.29–0.77) | 0.34 | (0–1.27) | 1.64 | (1.19–2.09) | 3.98 | (3.31–4.64) | |
| 2005–2009 | 12,775 | 0.66 | (0.50–0.83) | 0.43 | (0–1.58) | 1.37 | (1.02–1.72) | 3.67 | (3.20–4.14) | |
| Modular THAs with | 1995–1999 | 37,848 | 0.43 | (0.36–0.49) | 0.40 | (0.33–0.46) | 1.18 | (0.67–1.69) | 2.60 | (2.44–2.77) |
| 2000–2004 | 69,052 | 0.49 | (0.44–0.55) | 0.47 | (0.41–0.52) | 0.69 | (0.39–0.99) | 2.21 | (2.10–2.32) | |
| 2005–2009 | 75,929 | 0.71 | (0.64–0.77) | 0.67 | (0.60–0.73) | 0.78 | (0.44–1.12) | 2.60 | (2.46–2.75) | |
a Adjusted for age and sex.
b Cumulative 5-year revision rates probably were underestimates due to incomplete 5-year follow-up.
Adjusted relative risks of revision due to infection for 4 different time intervals after primary surgery, for the 3 time periods. Adjusted for age, sex, diagnosis, prosthesis, and cement
| Time after | Number | Number of | Adjusted risk ratio | 95% CI | p-value |
|---|---|---|---|---|---|
| 0–3 months | |||||
| 1995–1999 | 113,280 | 74 | 1 | ||
| 2000–2004 | 147,823 | 175 | 1.9 | 1.4–2.4 | <0.001 |
| 2005–2009 | 171,065 | 535 | 4.8 | 3.7–6.2 | <0.001 |
| 3–12 months | |||||
| 1995–1999 | 111,607 | 142 | 1 | ||
| 2000–2004 | 145,625 | 206 | 1.3 | 1.0–1.6 | 0.05 |
| 2005–2009 | 168,019 | 216 | 1.2 | 1.0–1.5 | 0.09 |
| 1–2 years | |||||
| 1995–1999 | 109,178 | 164 | 1 | ||
| 2000–2004 | 142,589 | 195 | 1.1 | 0.9–1.3 | 0.6 |
| 2005–2009 | 164,758 | 175 | 1.0 | 0.8–1.3 | 0.9 |
| > 2 years | |||||
| 1995–1999 | 105,338 | 398 | 1 | ||
| 2000–2004 | 138,270 | 361 | 0.9 | 0.8–1.1 | 0.5 |
| 2005–2009 | 126,131 | 137 | 0.9 | 0.7–1.1 | 0.2 |
Adjusted relative risks and adjusted cumulative 5-year revision rates for risk factors for revision due to infection. All risk factors were adjusted mutually for the other risk factors in addition to the year of primary surgery. Follow-up in the risk analyses was 1-16 years
| Number | Number of | Adjusted risk ratio | 95% | p-value | Adjusted cumulative | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| <40 | 5,590 | 39 | 1 | 0.47 | ||
| 40–51 | 74,107 | 515 | 1.1 | 0.8–1.5 | 0.6 | 0.59 |
| 60–69 | 129,134 | 854 | 1.1 | 0.8–1.5 | 0.7 | 0.58 |
| 70–79 | 157,292 | 1,021 | 1.1 | 0.8–1.5 | 0.6 | 0.62 |
| 80–89 | 63,034 | 337 | 0.9 | 0.7–1.3 | 0.8 | 0.52 |
| ≥90 | 3,011 | 12 | 0.7 | 0.4–1.4 | 0.3 | 0.32 |
| Sex | ||||||
| Female | 266,42 | 1,312 | 1 | 0.46 | ||
| Male | 165,748 | 1,466 | 1.9 | 1.8–2.1 | <0.001 | 0.87 |
| Diagnosis | ||||||
| Osteoarthritis | 345,925 | 2,090 | 1 | 0.54 | ||
| Hip fracture | 33,572 | 327 | 2.1 | 1.9–2.4 | <0.001 | 1.12 |
| Inflammatory disease | 15,771 | 118 | 1.4 | 1.1–1.7 | 0.001 | 0.72 |
| Childhood hip disease | 14,983 | 80 | 0.9 | 0.7–1.2 | 0.6 | 0.51 |
| Femoral head necrosis | 9,671 | 92 | 1.7 | 1.4–2.1 | <0.001 | 0.87 |
| Other diagnoses | 12,246 | 71 | 1.3 | 1.0–1.6 | 0.06 | 0.65 |
| Prosthesis | ||||||
| Modular | 388,371 | 2,475 | 1 | 0.58 | ||
| Monoblock | 43,797 | 303 | 1.1 | 1.0–1.3 | 0.09 | 0.69 |
| Fixation | ||||||
| Uncemented | 90,177 | 542 | 1 | 0.54 | ||
| Cemented | 288,053 | 1,798 | 1.1 | 1.0–1.2 | 0.09 | 0.58 |
| Hybrid | 36,922 | 337 | 1.6 | 1.4–1.8 | <0.001 | 0.79 |
| Inverse hybrid | 17,016 | 101 | 1.0 | 0.8–1.3 | 0.7 | 0.53 |
| Cement | ||||||
| With antibiotics | 316,072 | 1,997 | 1 | 0.58 | ||
| Without antibiotics | 25,921 | 239 | 1.5 | 1.3–1.8 | <0.001 | 0.96 |